Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 124

Related Citations for PubMed (Select 23442012)

1.

Lenalidomide and thalidomide in the treatment of chronic pain.

Asher C, Furnish T.

Expert Opin Drug Saf. 2013 May;12(3):367-74. doi: 10.1517/14740338.2013.775242. Epub 2013 Feb 27. Review.

PMID:
23442012
2.

Use of lenalidomide in treating refractory prurigo nodularis.

Liu H, Gaspari AA, Schleichert R.

J Drugs Dermatol. 2013 Mar;12(3):360-1.

PMID:
23545923
3.

Novel immunomodulatory compounds in multiple myeloma.

Saini N, Mahindra A.

Expert Opin Investig Drugs. 2013 Feb;22(2):207-15. doi: 10.1517/13543784.2013.749235. Epub 2012 Dec 25. Review.

PMID:
23265189
4.

Lenalidomide in the treatment of chronic lymphocytic leukemia.

Gentile M, Recchia AG, Vigna E, Mazzone C, Lucia E, Gigliotti V, Bossio S, Madeo A, Morabito L, Servillo P, Franzese S, Caruso N, De Stefano L, Bisconte MG, Gentile C, Morabito F.

Expert Opin Investig Drugs. 2011 Feb;20(2):273-86. doi: 10.1517/13543784.2011.546343. Epub 2011 Jan 10. Review.

PMID:
21214505
5.

Thalidomide-derived immunomodulatory drugs as therapeutic agents.

Galustian C, Labarthe MC, Bartlett JB, Dalgleish AG.

Expert Opin Biol Ther. 2004 Dec;4(12):1963-70. Review.

PMID:
15571458
6.

Thalidomide and lenalidomide in multiple myeloma.

Mazumder A, Jagannath S.

Best Pract Res Clin Haematol. 2006;19(4):769-80. Review.

PMID:
16997182
7.

Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma.

Bringhen S, Gay F, Pautasso C, Cerrato C, Boccadoro M, Palumbo A.

Expert Opin Drug Metab Toxicol. 2012 Sep;8(9):1209-22. doi: 10.1517/17425255.2012.712685. Epub 2012 Aug 3. Review.

PMID:
22862790
8.

Lenalidomide: an immunomodulatory drug.

Crane E, List A.

Future Oncol. 2005 Oct;1(5):575-83. Review.

PMID:
16556034
9.

Lenalidomide and chronic lymphocytic leukemia.

González-Rodríguez AP, Payer AR, Acebes-Huerta A, Huergo-Zapico L, Villa-Alvarez M, Gonzalez-García E, Gonzalez S.

Biomed Res Int. 2013;2013:932010. doi: 10.1155/2013/932010. Epub 2013 Sep 19. Review.

10.

The potential of immunomodulatory drugs in the treatment of solid tumors.

Dalgleish A, Galustian C.

Future Oncol. 2010 Sep;6(9):1479-84. doi: 10.2217/fon.10.105. Review.

PMID:
20919830
11.

Lenalidomide: the emerging role of a novel targeted agent in malignancies.

Kalmadi S, Baz R, Mahindra A.

Drugs Today (Barc). 2007 Feb;43(2):85-95. Review.

PMID:
17353946
12.

[IMiDs in hematology].

Wémeau M, Gauthier J, Leleu X, Yakoub-Agha I.

Bull Cancer. 2011 Aug;98(8):879-87. doi: 10.1684/bdc.2011.1404. Review. French.

PMID:
21827980
13.

The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: a clinical practice guideline.

Leitch HA, Buckstein R, Shamy A, Storring JM.

Crit Rev Oncol Hematol. 2013 Feb;85(2):162-92. doi: 10.1016/j.critrevonc.2012.07.003. Epub 2012 Aug 15. Review.

PMID:
22901762
14.

IMiDs: a novel class of immunomodulators.

Knight R.

Semin Oncol. 2005 Aug;32(4 Suppl 5):S24-30. Review.

PMID:
16085014
15.

[Current therapeutic indications of thalidomide and lenalidomide].

Ordi-Ros J, Cosiglio FJ.

Med Clin (Barc). 2014 Apr 22;142(8):360-4. doi: 10.1016/j.medcli.2013.04.038. Epub 2013 Jul 3. Review. Spanish.

PMID:
23830554
16.

A review of the history, properties, and use of the immunomodulatory compound lenalidomide.

Zeldis JB, Knight R, Hussein M, Chopra R, Muller G.

Ann N Y Acad Sci. 2011 Mar;1222:76-82. doi: 10.1111/j.1749-6632.2011.05974.x. Review.

PMID:
21434945
17.

Role of lenalidomide in the treatment of multiple myeloma and myelodysplastic syndrome.

Maier SK, Hammond JM.

Ann Pharmacother. 2006 Feb;40(2):286-9. Epub 2006 Jan 10. Review.

PMID:
16403850
18.

Lenalidomide in lymphomas and chronic lymphocytic leukemia.

Wiernik PH.

Expert Opin Pharmacother. 2013 Mar;14(4):475-88. doi: 10.1517/14656566.2013.765858. Epub 2013 Jan 29. Review.

PMID:
23356486
19.

Lenalidomide as a novel treatment of acute myeloid leukemia.

Chen Y, Borthakur G.

Expert Opin Investig Drugs. 2013 Mar;22(3):389-97. doi: 10.1517/13543784.2013.758712. Epub 2013 Jan 15. Review.

PMID:
23316859
20.

The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes.

Palumbo A, Freeman J, Weiss L, Fenaux P.

Expert Opin Drug Saf. 2012 Jan;11(1):107-20. doi: 10.1517/14740338.2011.619975. Epub 2011 Nov 9. Review.

PMID:
22066855
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk